Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003545 · ClinicalTrials.gov registry record · Phase 2

506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

A Phase 2 study of Lymphoma and Leukemia, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
35
Enrollment target
20
Study locations

NCT00003545 is a Phase 2 study of Lymphoma and Leukemia that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 35 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003545, a Phase 2 study of Lymphoma and Leukemia, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
35 participants
Enrollment target
20
Study locations

Study Summary

Phase II trial to study the effectiveness of 506U78 in treating patients with refractory or relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

Conditions Studied

Lymphoma Leukemia

Interventions

  • DRUG nelarabine

Study Locations (20)

California

  • Cancer Center and Beckman Research Institute, City of Hope - Duarte
  • Veterans Affairs Medical Center - Long Beach - Long Beach
  • USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
  • Veterans Affairs Medical Center - West Los Angeles - Los Angeles
  • Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
  • Veterans Affairs Outpatient Clinic - Martinez - Martinez
  • CCOP - Bay Area Tumor Institute - Oakland
  • Chao Family Comprehensive Cancer Center - Orange
  • University of California Davis Medical Center - Sacramento
  • CCOP - Santa Rosa Memorial Hospital - Santa Rosa
  • Stanford University - Stanford
  • David Grant Medical Center - Travis Air Force Base

Arizona

  • CCOP - Greater Phoenix - Phoenix
  • Veterans Affairs Medical Center - Phoenix (Hayden) - Phoenix
  • Veterans Affairs Medical Center - Tucson - Tucson
  • Arizona Cancer Center - Tucson

Arkansas

  • University of Arkansas for Medical Sciences - Little Rock
  • Veterans Affairs Medical Center - Little Rock (McClellan) - Little Rock

Alabama

  • MBCCOP - Gulf Coast - Mobile

Colorado

  • University of Colorado Cancer Center - Denver

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 1998-08
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00003545

The ClinicalTrials.gov registry entry for NCT00003545 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (93% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which nelarabine is the first listed.

NCT00003545 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Arkansas.

Frequently Asked Questions

What is clinical trial NCT00003545 about?

NCT00003545 is a clinical study titled "506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma". Phase II trial to study the effectiveness of 506U78 in treating patients with refractory or relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

What is the current status of trial NCT00003545?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 1998-08.

What conditions does trial NCT00003545 study?

This clinical trial studies the following conditions: Lymphoma, Leukemia.

What interventions are being tested in trial NCT00003545?

The interventions under investigation include: nelarabine (DRUG).

Who is sponsoring clinical trial NCT00003545?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00003545 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphoma

All registered trials for this condition

Leukemia

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.